Brought to you by 
Solvay licenses Pronova Biocare's Omacor in certain European regions
10 May 2022
Executive Summary
Solvay Pharmaceuticals (therapeutics within the areas of cardiology, gastroenterology, mental health, and hormone replacements) received a license to market Omacor, a cardiology product from Pronova Biocare (Omega-3 fatty acids), a business unit of Norsk Hydro's Hydro Pronova subsidiary.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Solvay licenses Pronova Biocare's Omacor in certain European regions
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice